Compare NBIX & HMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | HMY |
|---|---|---|
| Founded | 1992 | 1950 |
| Country | United States | South Africa |
| Employees | N/A | 34350 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 9.8B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | HMY |
|---|---|---|
| Price | $158.25 | $15.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 2 |
| Target Price | ★ $180.91 | $16.00 |
| AVG Volume (30 Days) | 1.2M | ★ 4.5M |
| Earning Date | 05-05-2026 | 02-04-2016 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $37.43 |
| Revenue Next Year | $13.14 | $27.44 |
| P/E Ratio | $83.53 | ★ $15.60 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $117.84 | $13.03 |
| 52 Week High | $162.39 | $26.04 |
| Indicator | NBIX | HMY |
|---|---|---|
| Relative Strength Index (RSI) | 75.63 | 42.54 |
| Support Level | $125.54 | $14.93 |
| Resistance Level | $158.92 | $16.21 |
| Average True Range (ATR) | 4.50 | 0.53 |
| MACD | 2.55 | 0.03 |
| Stochastic Oscillator | 89.50 | 22.70 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.